Your browser doesn't support javascript.
loading
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
Schreiber, Anna R; Kagihara, Jodi A; Corr, Bradley R; Davis, S Lindsey; Lieu, Christopher; Kim, Sunnie S; Jimeno, Antonio; Camidge, D Ross; Williams, Jud; Heim, Amy M; Martin, Anne; DeMattei, John A; Holay, Nisha; Triplett, Todd A; Eckhardt, S Gail; Litwiler, Kevin; Winkler, James; Piscopio, Anthony D; Diamond, Jennifer R.
Afiliação
  • Schreiber AR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Kagihara JA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Corr BR; Division of Medical Oncology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA.
  • Davis SL; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Lieu C; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Kim SS; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Jimeno A; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Camidge DR; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Williams J; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Heim AM; OnKure, Inc., Boulder, CO 80301, USA.
  • Martin A; OnKure, Inc., Boulder, CO 80301, USA.
  • DeMattei JA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Holay N; OnKure, Inc., Boulder, CO 80301, USA.
  • Triplett TA; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
  • Eckhardt SG; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
  • Litwiler K; Department of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA.
  • Winkler J; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
  • Piscopio AD; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77054, USA.
  • Diamond JR; OnKure, Inc., Boulder, CO 80301, USA.
Cancers (Basel) ; 16(1)2023 Dec 23.
Article em En | MEDLINE | ID: mdl-38201519
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article